Previous 10 | Next 10 |
Immunic to Participate in Industry and Investor Conferences in September PR Newswire NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule t...
(NewsDirect) Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive...
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire – Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 – – Full Data Readout Expected in Ap...
--News Direct-- Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business d...
2023-08-06 01:59:07 ET Immunic, Inc. (IMUX) Q2 2023 Earnings Conference Call August 3, 2023, 08:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants ...
2023-08-03 06:42:30 ET Immunic press release ( NASDAQ: IMUX ): Q2 GAAP EPS of -$0.54 misses by $0.01 . Cash, Cash Equivalents and Investments as of June 30, 2023 were $77.3 million. With these funds, Immunic expects to be able to fund its operations into the fourth qua...
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire – Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in...
Immunic to Participate in Investor and Scientific Conferences in August PR Newswire NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule th...
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK , July 27, 2023 /PRNewswire/ -- Immu...
(NewsDirect) Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS) treatment. Dr Vitt gives an overview of the treatment that Immunic is ...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...